Gilead Sciences Receives FDA Warning Letter
On September 21, 2010, Gilead Sciences (San Dimas, CA) received a warning letter from the US Food and Drug Administration, citing violations of current good manufacturing practices (cGMP) for its manufacturing and quality processes related to the production of antifungal agent AmBisome at its California facility.
On September 21, 2010, Gilead Sciences (San Dimas, CA) received a warning letter from the US Food and Drug Administration, citing violations of current good manufacturing practices (cGMP) for its manufacturing and quality processes related to the production of antifungal agent AmBisome at its California facility.
The key deviation cited was that the company failed to maintain defined areas or control systems that are necessary to prevent contamination or mixups during aseptic processing. Also, the company’s environmental monitoring program was not adequate in the aseptic filling areas and the practice used to assess unidirectional airflow in the critical product path was inadequate to prevent product contamination.
Other deviations cited in the warning letter were related to inappropriate written procedures for production and process controls designed to ensure the drug product’s identity, strength, quality, and purity. The letter also said that the company had not cleaned and maintained equipment at appropriate intervals to prevent contamination.
FDA inspectors visited the plant early in the year, and Gilead responded to those concerns on March 2, 2010. The warning letter said that the response lacked sufficient corrective actions. Gilead Sciences now has 15 days to respond to the warning letter.
FDA warning letter
http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm227649.htm
Teva and Samsung Bioepis Launch Biosimilar Eculizumab in US Market
April 17th 2025Eculizumab-aagh (EPYSQLI) is now available in the US to treat patients living with difficult-to-treat rare diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Top 10 Cleanroom Problems That Can Be Prevented via Preventative Maintenance
April 14th 2025Cleanrooms require strict environmental control to maintain sterility, prevent contamination, and ensure seamless operations. Without a proactive preventative maintenance (PM) program, various issues can arise, leading to costly downtime, contamination risks, and operational inefficiencies. Below are ten common cleanroom problems that can be effectively mitigated through proper PM practices.
